

Supplementary Figure 1. MRPS23 was highly expressed in glioma and correlated with adverse clinical outcomes in glioma patients. (A) MRPS23 is highly expressed in glioma tissues examined by HPA database. (B—D) High expression of MRPS23 correlated with adverse clinical features in glioma patients, examined by CGGA dataset. (E, F) High expression of MRPS23 correlated with adverse clinical outcomes in glioma patients, examined by CGGA and Rembrandt dataset. (G—I) High expression of MRPS23 positively correlated with m6A methylation regulator in glioma patients, examined by CGGA and Rembrandt dataset.